Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.8 USD | +0.45% | +1.30% | -31.64% |
Apr. 20 | Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing | MT |
Apr. 20 | Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing | MT |
Business Summary
Number of employees: 164
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Salzmann
CEO | Chief Executive Officer | 56 | 19-05-31 |
Eva Barnett
DFI | Director of Finance/CFO | 44 | 21-10-03 |
Sheetal Patel
CTO | Chief Tech/Sci/R&D Officer | - | - |
Ian Gourley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Maria Alba
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jennifer Moseley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-08-23 |
Jay Stout
CTO | Chief Tech/Sci/R&D Officer | 61 | 23-03-31 |
Chief Tech/Sci/R&D Officer | 66 | 21-05-31 | |
Chau Cheng
IRC | Investor Relations Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 19-12-17 |
Andrew Fromkin
BRD | Director/Board Member | 58 | 19-12-17 |
Douglas Hughes
BRD | Director/Board Member | 62 | 19-12-17 |
Atul Pande
BRD | Director/Board Member | 69 | 19-12-17 |
Frank Torti
CHM | Chairman | 45 | 19-12-17 |
Eric Venker
BRD | Director/Board Member | 37 | 20-02-17 |
Peter Salzmann
CEO | Chief Executive Officer | 56 | 19-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 145,292,970 | 62,278,831 ( 42.86 %) | 0 | 42.86 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.64% | 4.18B | |
+4.09% | 43.84B | |
+46.28% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- IMVT Stock
- Company Immunovant, Inc.